Description
An adenosine A2A receptor antagonist; selective for adenosine A2A over A1 receptors (Kis = 2.3 and 107 nM, respectively, in radioligand binding assays); inhibits agonist-induced production of cAMP in CHO cells expressing adenosine A2A receptors (IC50 = 353 nM); reduces haloperidol-induced catalepsy in mice at 10 and 20 mg/kg; reduces the number of jaw tremors in a rat model of tacrine-induced Parkinsonian jaw tremors; increases locomotor activity and reverses motor disabilities in a marmoset model of MPTP-induced Parkinson’s disease at 20 and 40 mg/kg
Formal name: 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine
Synonyms:
Molecular weight: 272.3
CAS: 496955-42-1
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease